Basics Roivant Sciences Ltd. Common Shares IPO Date: January 1, 2021 Sector: Healthcare Industry: Biotech Market Cap: $8.82B Activated in VL: True Average Daily Range Avg Daily Range: $0.20 | 2.47% Avg Daily Range (30 D): $0.13 | 1.11% Avg Daily Range (90 D): $0.16 | 1.37% Institutional Daily Volume Avg Daily Volume: 2.73M Avg Daily Volume (30 D): 4.36M Avg Daily Volume (90 D): 4.87M Trade Size Avg Trade Size (Sh.): 149 Avg Trade Size (Sh.) (30 D): 146 Avg Trade Size (Sh.) (90 D): 162 Institutional Trades Total Inst.Trades: 2,750 Avg Inst. Trade: $3.47M Avg Inst. Trade (30 D): $3.66M Avg Inst. Trade (90 D): $4.35M Avg Inst. Trade Volume: .33M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $8.13M Avg Closing Trade (30 D): $7.11M Avg Closing Trade (90 D): $9.42M Avg Closing Volume: 759.05K     News Sep 4, 2025 @ 11:00 AM Pulmovant Receives Orphan Drug Designation in Japa... Source: Pulmovant Sep 3, 2025 @ 4:57 PM Immunovant Unveils Durability and Treatment-Free S... Source: Immunovant, Inc. Feb 20, 2025 @ 8:22 AM Will Moderna Stock Drop to $25? 1 Wall Street Anal... Source: Eric Volkman Oct 28, 2024 @ 1:25 PM Organon Completes Acquisition of Dermavant, includ... Source: Globe Newswire Sep 18, 2024 @ 7:20 PM Roivant Sciences Offloads Psoriasis Medicine Maker... Source: Benzinga Editor Financials   TTM Q1 2026 Q4 2025 Basic EPS $-.7 $-.33 $-.29 Diluted EPS $-.7 $-.33 $-.29 Revenue $ 23.23M $ 2.17M $ 7.57M Gross Profit $ $ $ Net Income / Loss $ -688.14M $ -273.91M $ -252.38M Operating Income / Loss $ -1185.98M $ -284.92M $ -284.97M Cost of Revenue $ $ $ Net Cash Flow $ -4448.99M $ -1477.87M $ 724.48M PE Ratio